JB Chemicals & Pharmaceuticals registered 45.30% decline in net profit to Rs 106.71 million for the quarter ended Dec. 31, 2007 from Rs 195.09 million in the corresponding quarter, last fiscal.                

Net sales stood at Rs 1,390.17 million in the quarter ended Dec. 31, 2007, as against Rs 1,351 million in the same period last year, recording a growth of 2.90%.

Total income reported a 7.01% increase to Rs 1,470.89 million for the quarter ended Dec. 31, 2007 from Rs 1,374.50 million in the same period, last year.

The diluted earning per share after, extra ordinary items, on Dec. 31, 2007 works out to Rs 1.27.

JB Chemicals & Pharmaceuticals is the flagship company of the Unique group. It is a manufacturer of basic chemicals, petrochemicals, pharmaceuticals, photographic chemicals and agro-based products. Its product portfolio includes metrogyl, rantac (a ranitidine-based formulation), and nicardia (a cardiac care medicine).

The company`s APIs include (metronidazole and its intermediates, diclofenac sodium, potassium and other salts of diclofenac and nifedipine), tablets, injectables (SVP and LVP), liquid suspensions, syrups and ointments markets. It has 11 manufacturing facilities across four locations.

Shares of the company declined Rs 3.4, or 5.31%, to settle at Rs 60.6. The total volume of shares traded was 76,592 at the BSE. (Wednesday)